Zevra Therapeutics (NASDAQ:ZVRA) Announces Quarterly Earnings Results

Zevra Therapeutics (NASDAQ:ZVRA) released its quarterly earnings data on Tuesday. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.10, FiscalAI reports. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. The firm had revenue of $37.76 million for the quarter, compared to analyst estimates of $37.08 million.

Here are the key takeaways from Zevra Therapeutics’ conference call:

• MIPLYFFA sales accelerated: Third-quarter revenue rose 45% year over year to $37.8 million, including $34 million in U.S. MIPLYFFA sales, which increased 12.6% from Q2. The company reported 197 cumulative prescription enrollment forms, 69% payer coverage, and strong refill and retention rates.
• Zevra believes the U.S. NPC market may be larger than its original estimate of 300–350 diagnosed patients, citing a steady flow of newly diagnosed patients and claims-data analysis. It modestly expanded its commercial team and plans to submit an sNDA in the first quarter of 2027 to potentially include patients younger than 24 months.
• The European review of arimoclomol is ongoing, with an expert group and the CHMP expected to evaluate the data; Zevra continues to expect a CHMP opinion in the fourth quarter. The outcome remains a significant regulatory uncertainty for expanding MIPLYFFA access in Europe.
• Zevra ended the quarter with $270.9 million in cash, cash equivalents, and investments, up $10.7 million sequentially, and reported net income of $19.2 million. The company said its balance sheet provides flexibility to expand MIPLYFFA access and advance its pipeline, including the 72-patient celiprolol DiSCOVER trial, which has recorded four confirmed events to date.

Zevra Therapeutics Stock Performance

ZVRA traded up $0.16 on Tuesday, reaching $10.26. The company had a trading volume of 688,233 shares, compared to its average volume of 1,217,035. The stock has a market cap of $609.28 million, a P/E ratio of 11.15 and a beta of 0.98. Zevra Therapeutics has a fifty-two week low of $8.01 and a fifty-two week high of $15.03. The company’s fifty day moving average is $11.14 and its 200 day moving average is $10.74.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, Director Corey Watton sold 12,300 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares in the company, valued at $20,250. This trade represents a 87.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Neil McFarlane sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $11.25, for a total value of $225,000.00. Following the sale, the chief executive officer owned 417,225 shares of the company’s stock, valued at approximately $4,693,781.25. This represents a 4.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ZVRA shares. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. BTIG Research dropped their price target on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Citizens Jmp increased their price target on Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, August 6th. Guggenheim cut their price target on Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a report on Friday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $26.00 price objective on shares of Zevra Therapeutics in a research report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $27.14.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.